Erzotabart is an IgG1-kappa monoclonal antibody that targets human CD38 (also known as ADP-ribosyl cyclase 1 or cyclic ADP-ribose hydrolase 1) and displays pronounced antineoplastic activity. Erzotabart acts by modulating CD38-mediated signaling pathways involved in tumor cell metabolism, proliferation, and immune evasion, making it a significant investigational candidate in oncology research.
Reinheit:
95.00%
CAS Nummer:
[2430792-01-9]
Target-Kategorie:
CD38
T82440
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten